Ladenburg Thalmann Financial Services Inc. Raises Stake in TherapeuticsMD Inc (TXMD)

Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of TherapeuticsMD Inc (NYSEMKT:TXMD) by 20.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,150 shares of the specialty pharmaceutical company’s stock after buying an additional 3,740 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in TherapeuticsMD were worth $128,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in TXMD. Sanders Morris Harris Inc. boosted its position in shares of TherapeuticsMD by 18.9% in the third quarter. Sanders Morris Harris Inc. now owns 506,100 shares of the specialty pharmaceutical company’s stock valued at $3,446,000 after buying an additional 80,500 shares in the last quarter. Rock Springs Capital Management LP boosted its position in shares of TherapeuticsMD by 14.3% in the third quarter. Rock Springs Capital Management LP now owns 1,800,000 shares of the specialty pharmaceutical company’s stock valued at $12,258,000 after buying an additional 225,000 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of TherapeuticsMD by 9.2% in the third quarter. BlackRock Fund Advisors now owns 5,059,418 shares of the specialty pharmaceutical company’s stock valued at $34,455,000 after buying an additional 426,991 shares in the last quarter. TD Asset Management Inc. boosted its position in shares of TherapeuticsMD by 3.5% in the third quarter. TD Asset Management Inc. now owns 551,300 shares of the specialty pharmaceutical company’s stock valued at $3,754,000 after buying an additional 18,400 shares in the last quarter. Finally, Aperio Group LLC purchased a new position in shares of TherapeuticsMD during the third quarter valued at about $164,000.

Institutional Ownership by Quarter for TherapeuticsMD (NYSEMKT:TXMD)

Shares of TherapeuticsMD Inc (NYSEMKT:TXMD) opened at 6.77 on Monday. The company has a 50 day moving average of $6.29 and a 200 day moving average of $6.22. TherapeuticsMD Inc has a 52-week low of $4.39 and a 52-week high of $9.29. The stock’s market capitalization is $1.34 billion.

TherapeuticsMD (NYSEMKT:TXMD) last issued its earnings results on Thursday, February 23rd. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.12). The company earned $4.49 million during the quarter, compared to analyst estimates of $5.91 million. During the same period in the prior year, the business earned ($0.10) earnings per share. TherapeuticsMD’s quarterly revenue was down 20.2% on a year-over-year basis. Analysts predict that TherapeuticsMD Inc will post ($0.40) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Ladenburg Thalmann Financial Services Inc. Raises Stake in TherapeuticsMD Inc (TXMD)” was published by Mideast Time and is the property of of Mideast Time. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.mideasttime.com/ladenburg-thalmann-financial-services-inc-raises-stake-in-therapeuticsmd-inc-txmd/1589078.html.

TXMD has been the topic of several research analyst reports. Goldman Sachs Group Inc restated a “buy” rating and set a $10.50 target price on shares of TherapeuticsMD in a research report on Sunday, December 4th. Jefferies Group LLC restated a “positive” rating and set a $18.00 target price on shares of TherapeuticsMD in a research report on Wednesday, January 25th. Cantor Fitzgerald initiated coverage on shares of TherapeuticsMD in a research report on Friday, December 16th. They set an “overweight” rating on the stock. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $15.00 target price (up from $12.00) on shares of TherapeuticsMD in a research report on Friday, March 3rd. Finally, Zacks Investment Research lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Thursday, January 5th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $20.71.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NYSEMKT:TXMD).

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.